Chemotherapy and diffuse low-grade gliomas : a survey within the European Low-Grade Glioma Network

Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherap
Background: Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial.
Methods: An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients.
Results: The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression.
Conclusions: The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
show moreshow less

Download full text files

Export metadata

  • Export Bibtex
  • Export RIS
Metadaten
Author:Amélie Darlix, Emmanuel Mandonnet, Christian Franz Freyschlag, Daniel Pinggera, Marie-Thérèse Forster, Martin Voss, Joachim Peter Steinbach, Carmel Loughrey, John Goodden, Giuseppe Banna, Concetta Di Blasi, Nicolas Foroglou, Andreas F. Hottinger, Marie-Hélène Baron, Johan Pallud, Hugues Duffau, Geert-Jan Rutten, Fabien Almairac, Denys Fontaine, Luc Taillandier, Catarina Viegas, Luisa Albuquerque, Gord von Campe, Tadeja Urbanic Purkart, Marie Blonski
URN:urn:nbn:de:hebis:30:3-508621
DOI:http://dx.doi.org/10.1093/nop/npy051
ISSN:2054-2585
ISSN:2054-2577
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=31386080
Parent Title (English):Neuro-oncology practice
Publisher:Oxford Univ. Press
Place of publication:Oxford
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/12/13
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2019/09/02
Tag:PCV; chemotherapy; clinical practice; diffuse low-grade glioma; temozolomide
Volume:6
Issue:4
Pagenumber:10
First Page:264
Last Page:273
Note:
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
HeBIS PPN:453937152
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0

$Rev: 11761 $